Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder
NCT ID: NCT03109379
Last Updated: 2020-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
43 participants
INTERVENTIONAL
2017-04-04
2019-09-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury
NCT03168828
URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
NCT04211831
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
NCT00768521
Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence
NCT04227184
Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder
NCT00196404
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TAR-302-5018 (42-day Indwelling)
Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.
Trospium-Releasing Intravesical System (TAR-302-5018)
TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
TAR-302-5018 (84-day Indwelling)
Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 84. TAR-302-5018 releases trospium gradually during the 84 day indwelling time.
Trospium-Releasing Intravesical System (TAR-302-5018)
TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trospium-Releasing Intravesical System (TAR-302-5018)
TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 8 or more voids per 24 hours as recorded in a diary
* At least 4 incontinence episodes associated with urgency recorded in a 3-day diary.
* At least 1 episode must occur per each 24 hour day
2. Inadequate response or limiting side effects with anticholinergics for the treatment of OAB
1. Symptoms of idiopathic overactive bladder (iOAB) (frequency/urgency) with urge urinary incontinence or mixed urinary incontinence with a predominant urge component for at least 6 months.
* 8 or more voids per 24 hours as recorded in a diary
* At least 4 incontinence episodes associated with urgency recorded in a 3-day diary.
1. At least 1 episode must occur per each 24 hour day
2. In the opinion of the investigator, the subject has experienced an inadequate response to or limiting side effects with prior oral medications for the treatment of OAB.
Exclusion Criteria
2. OAB caused by neurological condition.
3. Presence of significant renal dysfunction at screening (Glomerular Filtration Rate \<30 mL/min).
4. Presence of significant polyuria of any cause at screening (urine output \>4,000 mL/day).
5. History of pelvic radiation.
6. History of either bladder cancer or bladder pathology that the investigator deems unfit for study inclusion.
7. Active malignancies within 12 months with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome.
8. Subjects with any bladder or urethral anatomic feature that may prevent the safe placement, indwelling use, or removal of TAR 302 5018.
9. In the opinion of the investigator, the subject has a history of significant stress urinary incontinence.
10. Subjects with active bladder stones or history of bladder stones \<6 months prior to study entry.
11. History of recurrent symptomatic urinary tract infections (UTIs) (\>4 per 1 year).
12. Subjects with either urinary retention or gastric retention or uncontrolled narrow-angle glaucoma.
13. A post-void residual volume (PVR) of 300 mL or greater
14. Subjects with known hypersensitivity to trospium, chemically-related drugs, or component excipients.
15. Subjects with known hypersensitivity to the device materials, including silicone and nitinol.
16. Subjects actively taking oral trospium.
17. The addition of a new or a change in dose to a current medication for the treatment of OAB (i.e. anticholinergics, beta-3 adrenergic agonists, antispasmodics, antidepressants, or hormones) within 30 days prior to signing the informed consent form (ICF). A stable dose must continue through the final study visit. If previously used and discontinued, these medications must have been stopped for \>2 weeks prior to Day 0.
18. Intravesical onabotulinum toxin use within the last 9 months prior to the Screening Visit.
19. Intravesical anticholinergic medications within the last 30 days prior to the Screening Visit.
20. History of non-medication based therapy (i.e. InterStim therapy) for the treatment of OAB. History of non-invasive neuromodulation (i.e. Percutaneous Tibial Nerve Stimulation (PTNS)) is allowed if discontinued at least 8 weeks prior to Study Day 0.
21. Female subject who is pregnant (as verified by urine test at time of screening) or lactating or of childbearing potential and not using acceptable methods of contraception.
22. Subject has a medical condition that may cause noncompliance with the study protocol.
23. Subject refuses to provide written informed consent.
24. Subject will be unable or unwilling to complete the questionnaires, diaries, or attend all protocol mandated study visits.
25. Participation in another drug, device, or behavioral study within 60 days prior to the Screening Visit.
26. History or presence of any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, gynecological, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder that, in the opinion of the investigator, contraindicates participation.
27. History of any of the following within 3 months prior to Screening Visit:
* Major illness/major surgery (requiring hospitalization), including pelvic, lower back surgery or procedure unrelated to bladder cancer; most outpatient procedures are not exclusionary
* Renal or ureteral stone disease or instrumentation
* Childbirth
28. Difficulty providing blood samples.
29. Other unspecified reasons that, in the opinion of the investigator or TARIS, make the subject unsuitable for enrollment.
1. Age \<18 years.
2. Neurologic bladder condition.
3. Subjects with Diabetes Mellitus (both Type 1 \& Type 2) must demonstrate optimal glycemic control with HbA1c levels \< 7.5 % and an absence of significant glucosuria defined as 3+ glucose via dipstick at screening.
4. Presence of significant polyuria of any cause at screening (urine output \>3,000 mL/day).
5. Presence of nocturnal polyuria at time of study screening defined as \>30% of total 24-hour urine collected from time of evening (P.M.) sleep and inclusive of the first morning (A.M.) void.
6. History of pelvic irradiation.
7. History of either bladder cancer or bladder pathology that the investigator deems unfit for study inclusion.
8. Currently uses intermittent catheterization (IC) to empty the bladder within 30 days of Day 0.
9. Subjects with any bladder or urethral anatomic feature (e.g., urethral stricture) that in the opinion of the investigator may prevent the safe placement, indwelling use, or removal of IP.
10. Subjects with active bladder stones or history of bladder stones \< 6 months prior to study entry.
11. Gross hematuria within 30 days of Day 0.
12. History of uncontrolled bleeding, bleeding diathesis, or underlying coagulopathy within 30 days of Day 0.
13. In the opinion of the investigator, the subject has a history of predominance of significant stress urinary incontinence.
14. History of \> 2 symptomatic urinary tract infections in the 6-months prior to Day 0.
15. Subjects with either urinary retention or gastric retention or uncontrolled narrow-angle glaucoma within 90 days of Day 0.
16. A post-void residual volume (PVR) of 100-mL or greater.
17. Subjects with known hypersensitivity to trospium, chemically-related drugs, or component excipients.
18. Subjects with known hypersensitivity to the device materials, including silicone and nitinol.
19. Anticholinergic or beta-3 agonist use for the treatment of urge urinary incontinence \< 2 weeks prior to Day 0.
20. History of intravesical onabotulinum toxin use within the last 9 months prior to the Screening Visit.
21. Intravesical anticholinergic medications within the last 14 days prior to the Screening Visit.
22. History of procedural-based neuromodulation therapy (e.g. InterStim therapy, Percutaneous Tibial Nerve Stimulation \[PTNS\]) for the treatment of OAB.
23. Female subject who is pregnant (as verified by serum test at time of screening) or lactating.
24. Subject has, in the opinion of the investigator, a medical condition that may cause noncompliance with the study protocol.
25. Subject who is unable or unwilling to complete the questionnaires, diaries, or attend all protocol mandated study visits.
26. Participation in another drug, device, or behavioral study within 60 days prior to the Screening Visit.
27. History or presence of any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, gynecological, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder, or other unspecified reasons that, in the opinion of the investigator or TARIS, make the subject unsuitable for enrollment.
28. History of any of the following within 3 months prior to Screening Visit:
i. Major illness/major surgery (requiring hospitalization), including pelvic, lower back surgery or procedure; most outpatient procedures are not exclusionary.
ii. Childbirth.
29. History of prostatic biopsy or surgery (ablative or non-ablative) within 6 months prior to Day 0.
30. History of significant pelvic organ prolapse (Grade \>/= 3).
31. Difficulty providing blood samples.
32. Known history of drug or alcohol dependency within 12 months of screening.
33. Other unspecified reasons that, in the opinion of the investigator or TARIS, make the subject unsuitable for enrollment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Taris Biomedical LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christopher Cutie, MD
Role: STUDY_DIRECTOR
TARIS Biomedical, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Urological Associates of Southern Arizona
Tucson, Arizona, United States
Medical Center for Clinical Research
San Diego, California, United States
Clinical Research Center of Florida
Pompano Beach, Florida, United States
DelRicht Clinical Research, LLC
New Orleans, Louisiana, United States
Bay State Clinical Trials, Inc
Watertown, Massachusetts, United States
William Beaumont Hospital - Royal Oak
Royal Oak, Michigan, United States
Michigan Institute of Urology
Troy, Michigan, United States
New Jersey Urology
Voorhees Township, New Jersey, United States
Accumed Research
Garden City, New York, United States
Manhattan Medical Resear
New York, New York, United States
UWCR - Lyndhurst Gynecologic Associates
Winston-Salem, North Carolina, United States
Urology of Virginia
Virginia Beach, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TAR-302-103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.